Results 211 to 220 of about 64,892 (357)

Chronic intestinal pseudo-obstruction in the course of systemic sclerosis successfully treated with intravenous immunoglobulins and rituximab. [PDF]

Reumatologia
Kołodziejczyk J, Ławińska I, Schmidt W, Leszczyński P, Pawlak-Buś K.   +4 more
europepmc   +1 more source

Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Children with primary immunodeficiency (PID) and secondary antibody deficiency (SAD) often require immunoglobulin replacement therapy due to low plasma immunoglobulin G (IgG) levels and recurrent infections. Existing pharmacokinetic models for immunoglobulin in PID patients predominantly focus on adults, with limited attention to ...
Iek Leng Cheng, Zhong Hui Huang, Austen Worth, Claire Booth, Joseph F. Standing   +4 more
wiley   +1 more source

Neutralization Activity of Standard and Hyperimmune Intravenous Immunoglobulins Against Recently Circulating SARS-CoV-2 Variants. [PDF]

Vaccines (Basel)
Liu D, Bellusci L, Golding H, Khurana S.
europepmc   +1 more source

Efficacy of Intravenous Immunoglobulins against Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids: A Case Report. [PDF]

Case Rep Neurol, 2023
Tsuchida T, Ura S, Yabe I.
europepmc   +1 more source

Haemolytic Anaemia Following High Dose Intravenous Immunoglobulin Treatment for Epidermolysis Bullosa Acquisita

, 2016
Sarah Madeline Brown, Philip Hampton
openalex   +2 more sources

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

The effect of high-dose long-term therapy of intravenous immunoglobulins in autoimmune autonomic and sensory small fiber neuropathy: a retrospective open-label controlled study. [PDF]

Sci Rep
Novak P, Witte A, Marciano SP, Felsenstein D, Ngo L.   +4 more
europepmc   +1 more source

Intravenous immunoglobulins for treatment of severe COVID-19-related acute encephalopathy. [PDF]

J Neurol, 2022
Huo S, Ferse C, Bösl F, Reincke SM, Enghard P, Hinrichs C, Treskatsch S, Angermair S, Eckardt KU, Audebert HJ, Ploner CJ, Endres M, Prüss H, Franke C, Scheibe F.   +14 more
europepmc   +1 more source

USE OF INTRAVENOUS IMMUNOGLOBULIN WITHIN THE IVF/ICSI PROTOCOL IN WOMEN WITH INFERTILITY AND ANTIPHOSPHOLIPID ANTIBODIES

, 2017
M. I. Krivonos, М. С. Зайнулина, Ekaterina A. Kornyushina, S. V. Chepanov, S. А. Selkov   +4 more
openalex   +2 more sources

Carrier‐free self‐assembled nanomedicine for combination‐therapy of acute myeloid leukemia

BMEMat, EarlyView.
CPDS combines drugs with three different mechanisms of action to achieve a multi‐mechanism combination therapy for AML by directly killing tumor cells and activating anti‐tumor immunity. Abstract As the main acute myeloid leukemia (AML) clinical treatment, the chemotherapy alone cannot meet the clinical therapeutic needs due to the high heterogeneity ...
Meihong Chai, Rui Zhang, Haiyin Yang, Jiyue Xing, Tianyuan Hu, Mengxi Zhu, Rui Li, Xiaoli Chen, Beibei Zhao, Yang Lan, Stefan Barth, Yuanyu Huang, Li Zhang, Mengjie Zhang, Huining He   +14 more
wiley   +1 more source